## Highlights of This Issue 813

### REVIEW

**815**  
The N-myc Oncogene: Maximizing its Targets, Regulation, and Therapeutic Potential  
Himisha Beltran  

### MCRRapidIMPACT

**823**  
HD Chromoendoscopy Coupled with DNA Mass Spectrometry Profiling Identifies Somatic Mutations in Microdissected Human Proximal Aberrant Crypt Foci  
David A. Drew, Thomas J. Devers, Michael J. O’Brien, Nicole A. Horelik, Joel Levine, and Daniel W. Rosenberg  

### CELL CYCLE AND SENESCENCE

**830**  
Androgen Receptor Promotes the Oncogenic Function of Overexpressed Jagged1 in Prostate Cancer by Enhancing Cyclin B1 Expression via Akt Phosphorylation  
Yongjiang Yu, Yu Zhang, Wenbin Guan, Tao Huang, Jian Kang, Xujun Sheng, and Jun Qi  

**843**  
ERβ Regulates NSCLC Phenotypes by Controlling Oncogenic RAS Signaling  
Fotis Nikolos, Christoforos Thomas, Gayani Rajapaksa, Igor Bado, and Jan-Åke Gustafsson  

### CELL DEATH AND SURVIVAL

**855**  
CAF-Secreted IGFBPs Regulate Breast Cancer Cell Anoikis  
Kelsey J. Weigel, Ana Jakimenko, Brooke A. Conti, Sarah E. Chapman, William J. Kaliney, W. Matthew Leevy, Matthew M. Champion, and Zachary T. Schafer  

**867**  
REDD1/DDIT4-Independent mTORC1 Inhibition and Apoptosis by Glucocorticoids in Thymocytes  
Nicholas C. Wolff, Renée M. McKay, and James Brugarolas  

### CHROMATIN, GENE, AND RNA REGULATION

**878**  
Dual Promoter Usage as Regulatory Mechanism of let-7c Expression in Leukemic and Solid Tumors  
Andrea Pelosi, Silvia Careccia, Giulia Sagrestani, Simona Nanni, Isabella Manni, Valeria Schinzari, Joost H.A. Martens, Antonella Farsetti, Hendrik G. Stunnenberg, Maria Pia Gentileschi, Donatella Del Bufalo, Ruggero De Maria, Giulia Piaggio, and Maria Giulia Rizzo  

### ONCOGENES AND TUMOR SUPPRESSORS

**901**  
Therapeutic Efficacy of p53 Restoration in Mdm2-Overexpressing Tumors  
Qin Li, Yun Zhang, Adel K. El-Naggar, Shushin Xiong, Peirong Yang, James G. Jackson, Gilda Chau, and Guillermima Lozano  

**912**  
Nullifying the CDKN2AB Locus Promotes Mutant K-ras Lung Tumorigenesis  
Katja Schuster, Niranjan Venkateswaran, Andrea Rabellino, Luc Girard, Samuel Peña-Llopis, and Pier Paolo Scaglioni  

**924**  
Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer  

### SIGNAL TRANSDUCTION

**940**  
Identification of mTORC2 as a Necessary Component of HRG/ErbB2-Dependent Cellular Transformation  

**953**  
Stress-Induced CXCR4 Promotes Migration and Invasion of Ewing Sarcoma  
Melanie A. Krook, Lauren A. Nicholls, Christopher A. Scannell, Rashmi Chugh, Dafydd G. Thomas, and Elizabeth R. Lawlor
ABOUT THE COVER

An aberrant crypt foci (ACF) obtained from the proximal (right) colon shows a distinct serrated morphology similar to that observed in human serrated adenomas (cover image). ACF are considered to represent the earliest macroscopically identifiable abnormality within the colorectal mucosa and can be routinely identified during high-definition chromoendoscopy. Importantly, these small lesions often harbor somatic mutations to colorectal cancer-associated oncogenes, including activating mutations to KRAS and BRAF. Furthermore, ACF provide valuable insight into the earliest stages of colorectal carcinogenesis and may serve as a surrogate marker of future cancer risk. For more information, see the article by Drew and colleagues on page 823.